<table border="single" id="id_4adf1a85-c44d-40ad-b09e-eeacc453f590" width="357.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_b424278a-8b2e-4720-a465-a038d751523d">Table 13. Established and Other Potentially Significant Drug Interactions</caption>
<col width="38.1%"></col>
<col width="26.6%"></col>
<col width="35.3%"></col>
<tbody>
<tr id="id_366ce13a-b61e-4471-9425-6dc5cfe85cd7">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Effect on Concentration of Lamotrigine or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Clinical Comment</td>
</tr>
<tr id="id_c6345a87-b05b-49bb-a3d4-968525bb06cf">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Estrogen-containing oral contraceptive preparation containing 30 mcg ethinylestradiol and 150 mcg levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine levels approximately 50%. </td>
</tr>
<tr id="id_0effcdde-6778-4976-81f7-bede42c79a5e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">↓ levonorgestrel</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease in levonorgestrel component by 19%</td>
</tr>
<tr id="id_8e952893-0847-4556-86e5-16a55886c78f">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Carbamazepine (CBZ) and CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Addition of carbamazepine decreases lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_0a7ef9f0-4261-447c-b741-d22913215a5e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? CBZ epoxide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May increase CBZ epoxide levels </td>
</tr>
<tr id="id_5efa362e-8d37-4b14-8583-ae7d5119b14a">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenobarbital/Primidone </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_27baf8df-7d49-42de-a0b4-9d437a56707e">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Phenytoin (PHT) </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine concentration approximately 40%. </td>
</tr>
<tr id="id_31a585c3-f3ce-40e0-8e66-78777eafe0ef">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ lamotrigine </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased lamotrigine AUC approximately 40%. </td>
</tr>
<tr id="id_22315c03-6ed9-48dc-b66a-b1a47737a160">
<td align="left" rowspan="2" stylecode="Lrule Botrule Rrule" valign="top">Valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑ lamotrigine </paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Increased lamotrigine concentrations slightly more than 2 fold. </td>
</tr>
<tr id="id_afa258b9-ac8b-461c-937d-476b36edc631">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">? valproate </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decreased valproate concentrations an average of 25% over a 3 week period then stabilized in healthy volunteers; no change in controlled clinical trials in epilepsy patients. </td>
</tr>
</tbody>
</table>